{
  "id": "fda_guidance_chunk_0303",
  "title": "Introduction - Part 303",
  "text": "Recommendations 8.2.8 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE COMPOSITION To document that the IRB/IEC is constituted in agreement with GCP X X (where required) 8.2.9 REGULATORY AUTHORITY(IES) AUTHORIZATION/APPROVAL/NOTIFICATION OF PROTOCOL (where required) To document appropriate authorization/approval/notification by the regulatory authority(ies) has been obtained prior to initiation of the trial in compliance with the applicable regulatory requirement(s) X (where required) X (where required) 8.2.10 CURRICULUM VITAE AND/OR OTHER RELEVANT DOCUMENTS EVIDENCING QUALIFICATIONS OF INVESTIGATOR(S) AND SUBINVESTIGATOR(S) To document qualifications and eligibility to conduct trial and/or provide medical supervision of subjects X X 8.2.11 NORMAL VALUE(S)/RANGE(S) FOR MEDICAL/LABORATORY/TECHNICAL PROCEDURES(S) AND/OR TEST(S) INCLUDED IN THE PROTOCOL To document normal values and/or ranges of the tests X X 8.2.12 MEDICAL/LABORATORY/TECHNICAL PROCEDURES/TESTS -Certification or -Accreditation or -Established quality control and/or external quality assessment or -Other validation (where required) To document competence of facility to perform required test(s), and support reliability of results X (where required) X 8.2.13 SAMPLE OF LABEL(S) ATTACHED TO INVESTIGATIONAL PRODUCT CONTAINER(S) To document compliance with applicable labelling regulations and appropriateness of instructions provided to the subjects X Contains Nonbinding Recommendations 8.2.14 INSTRUCTIONS FOR HANDLING OF INVESTIGATIONAL PRODUCT(S) AND TRIALRELATED MATERIALS (if not included in protocol or Investigator’s Brochure) To document instructions needed to ensure proper storage, packaging, dispensing, and disposition of investigational product(s) and trial-related materials X X 8.2.15 SHIPPING RECORDS FOR INVESTIGATIONAL PRODUCT(S) AND TRIAL-RELATED MATERIALS To document shipment dates, batch numbers and method of shipment of investigational product(s) and trial-related materials. Allows tracking of product batch, review of shipping conditions, and accountability X X 8.2.16 CERTIFICATE(S) OF ANALYSIS OF INVESTIGATIONAL PRODUCT(S) SHIPPED To document identity, purity, and strength of investigational product(s) to be used in the trial X 8.2.17 DECODING PROCEDURES FOR BLINDED TRIALS To document how, in case of an emergency, identity of blinded investigational product can be revealed without breaking the blind for the remaining subjects’ treatment X X (third party if applicable) 8.2.18 MASTER RANDOMIZATION LIST To document method for randomization of trial population X (third party if applicable) 8.2.19 PRE-TRIAL MONITORING REPORT To document that the site is suitable for the trial (may be combined with 8.2.20) X 8.2.20 TRIAL INITIATION MONITORING REPORT To document that trial procedures were reviewed with the investigator and the investigator’s trial staff (may be combined with 8.2.19) X X Contains Nonbinding Recommendations 8.3 During",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 405888,
  "end_pos": 407424,
  "tokens": 512,
  "tags": [
    "design",
    "statistical",
    "regulatory",
    "clinical_trial",
    "consent",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "mandatory",
  "created_at": "2025-10-23T02:25:44.699Z"
}